Table 3

Country-wide data stratified by diagnosis on bDMARD switches from an anti-TNF to a non-anti-TNF or to another anti-TNF and vice versa, in patients who filled bDMARD prescriptions for inflammatory rheumatic disease between 8/2016−7/2018

bDMARD switchesRheumatoid arthritis (n=2290)Psoriatic arthritis (n=1097)Ankylosing spondylitis (n=948)
From anti-TNF to non-anti-TNF (%)719 (31)448 (41)315 (33)
From one anti-TNF to another anti-TNF (%)738 (32)351 (32)514 (54)
From a non-anti-TNF to an anti-TNF (%)486 (21)167 (15)118 (12)
From non-anti-TNF to another non-anti-TNF (%)347 (15)131 (12)1 (0.1)
  • Non-anti-TNF bDMARDs include: Abatacept, Anakinra, Rituximab, Tocilizumab, Secukinumab, Ustekinumab.

  • bDMARD, biologic disease modifying anti-rheumatic drugs; TNF, tumour necrosis factor.